Facebook
Twitter
LinkedIn
ForwardMolecular-Targeted Therapies in Lung Cancer: Practical Application of Clinical Trials Data
This accredited continuing education activity “Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data”, is a half-day conference featuring leading experts in lung cancer who will provide a comprehensive overview of implications of actionable molecular alterations in lung cancer. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with lung cancer. This program features in-depth discussions and analysis of the latest scientific findings and practice-changing advances (including the data presented at the 2021 ASCO Annual Meeting in June, 2021) in molecular testing and targeted-therapies for lung cancer. Expert faculty will utilize didactics, case-based presentations and related panel discussions, and aim to place molecular testing into clinical context and discuss how the results may effectively contribute to patient care.
This educational activity will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:
- Role of different platforms, including next generation sequencing, in testing for actionable molecular alterations to identify targeted therapy options in lung cancer.
- Current and evolving paradigms in a biomarker driven precision oncology approach for management of lung cancer.
- Trends, challenges, controversies, and limitations of precision oncology approaches and targeted therapies in management of lung cancer.
Target Audience
- Oncologists
- Oncology Nurse Practitioners & Physician Assistants
- Oncology Pharmacists
- Oncology Nurses
- Residents/Fellow
- Researchers
REGISTRATION FEES
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-t employed by the industry" option when registering and the price will reset to $0.
Healthcare providers ($0.00)
Industry employees ($206)
If you are a healthcare provider involved in patient care and you are not employed by the Industry, please register for the course here
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review the role, including advantages and disadvantages, of different testing methodologies available for detecting molecular alterations in lung cancer.
- Interpret results of next generation sequencing and other biomarkers predictive of response to targeted therapies in lung cancer.
- Plan optimal molecular-targeted adjuvant and/or extended adjuvant strategies for patients with non-metastatic NSCLC.
- Integrate recent advances and available clinical data to optimally sequence molecular-targeted agents in the treatment of metastatic NSCLC.
- Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in clinical investigation for patients with NSCLC .
All times are listed in Pacific Time zone
7:15 AM to 8:00 AM PST: Registration/Networking
Session 1: Moderator - Dr. Kumar Prabhash
8:00 AM to 8:20 AM PST: Epidemiology of molecular alterations in lung cancer - Dr. Christina Merkhofer
8:20 AM to 9:15 AM PST: Methodologies for detection of molecular driver mutations in lung cancer, a case-based discussion - Dr. Tejas Patil
9:15 AM to 9:45 AM PST: Break
Session 2: Moderator - Dr. Tejas Patil
9:45 AM to 10:10 AM PST: Molecular-guided adjuvant therapy for lung cancer - Dr. Rafael Santana-Davila
10:10 AM to 10:35 AM PST: Molecular-guided therapy for metastatic lung cancer: Targeting EGFR, ROS1, ALK and BRAF – Dr. Kathryn Gold
10:35 AM to 11:00 AM PST: Molecular-guided therapy for metastatic lung cancer: Targeting MET, NTRK and RET - Dr. Wade Thomas Iams
11:00 AM to 12:00 PM PST: Emerging precision oncology approaches in management of lung cancer, a case-based discussion - Dr. Narjust Duma
12:00 PM PST: Adjourn
 | Narjust Duma, MDAssistant Professor of Medicine Dana-Farber Cancer Institute/Harvard University |  | Cristina Merkhofer, MDAssistant Professor of Medicine University of Washington Medical Oncologist Seattle Cancer Care Alliance |
 | Kathryn Gold, MDAssociate Professor of Medicine University of California, San Diego |  | Tejas Patil, MDAssistant Professor of Medicine University of Colorado |
 | Wade Iams, MDAssistant Professor of Medicine Vanderbilt University |  | Rafael Santana-Davila, MDAssociate Professor of Medicine University of Washington Medical Oncologist Seattle Cancer Care Alliance |
 | Kumar Prabhash, MDMedical Oncologist Tata Memorial Hospital, Mumbai, India |
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 3.5 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.5 Contact Hours.
ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Commercial Support Disclosure
Available Credit
- 3.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 3.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 3.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 0.00 Attendance
- 3.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.50 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
Cancellation Policy
You may cancel your registration anytime. No refunds will be issued for cancelled registration.
You must complete all required course objects to be able to claim continuing education (CE) credits or maintenance of certificate (MOC) points.
Required Hardware/software
This meeting will be held virtually. Registered attendees will be able to access the link to join the meeting by logging into their account and navigating to the "my pending activities" tab.
The meeting link will be activated 30-minutes before the activity start time.
Registration Fees
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-t employed by the industry" option when registering and the price will reset to $0.
Healthcare providers ($0.00)
Industry employees ($206)
If you are a healthcare provider involved in patient care and you are not employed by the Industry, please register for the course here
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.